BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:57 PM
 | 
Oct 10, 2012
 |  BC Extra  |  Company News

CHMP: mature OS data needed for Revlimid label expansion

EMA's CHMP reiterated on Wednesday that it needs mature overall survival data before it can make a decision on whether to approve an expanded label for multiple myeloma (MM) drug Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG). CHMP made the comments in a benefit-risk assessment report for a withdrawn application that had sought approval of Revlimid as maintenance treatment in...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >